Tenax Therapeutics Inc (TENX) — Titan Protect Analysis

TENX

Tenax Therapeutics Inc

Healthcare · ·

$10.73

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$293M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-7.84

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-51.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$30.00

+180% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 7 analysts covering this stock

About Tenax Therapeutics Inc

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was for

https://www.tenaxthera.com

Country: United States Employees: 14 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

1.172

Excellent risk-adjusted returns

Kelly Fraction

0.0855

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.846

Returns exceed worst-case losses — strong risk profile

Annual Return

76.6%

Historical annualised return based on price data

Max Drawdown

-41.5%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$18.38

42% below the year high

52W Low

$5.34

101% above the year low

Avg Volume

576,060

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.41

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-57,907,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$36.00

Target Median

$30.00

Target Low

$20.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go